Atria Investments Inc Invests $288,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Atria Investments Inc bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 7,978 shares of the specialty pharmaceutical company’s stock, valued at approximately $288,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Exchange Traded Concepts LLC lifted its stake in Supernus Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after acquiring an additional 560 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Supernus Pharmaceuticals by 0.5% in the fourth quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company’s stock valued at $6,236,000 after purchasing an additional 800 shares during the last quarter. Quartz Partners LLC lifted its position in shares of Supernus Pharmaceuticals by 3.0% during the fourth quarter. Quartz Partners LLC now owns 28,499 shares of the specialty pharmaceutical company’s stock valued at $1,031,000 after purchasing an additional 820 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 870 shares during the last quarter. Finally, KBC Group NV grew its position in Supernus Pharmaceuticals by 53.1% in the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 929 shares in the last quarter.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This represents a 6.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 in the last 90 days. 9.30% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $32.16 on Tuesday. The stock has a market capitalization of $1.79 billion, a P/E ratio of 30.06 and a beta of 0.83. The stock’s 50-day simple moving average is $36.13 and its 200 day simple moving average is $35.15. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on SUPN shares. Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.